Zai Lab Limited (HKG:9688)

Market Cap	32.09B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.96B
Shares Out	n/a
EPS (ttm)	-19.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,651,967
Average Volume	15,042,278
Open	28.90
Previous Close	29.50
Day's Range	28.00 - 28.90
52-Week Range	12.32 - 35.50
Beta	0.95
RSI	51.33
Earnings Date	Aug 7, 2025

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 1,869
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9688

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Financial numbers in USD